JP5030383B2 - 生物活性化合物を含む表面コーティング - Google Patents

生物活性化合物を含む表面コーティング Download PDF

Info

Publication number: JP5030383B2
Authority: JP; Japan
Prior art keywords: group; peo; medical device; factor; complement
Prior art date: 2002-10-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

JP2004546970A

Other languages

English (en)

Japanese (ja)

Other versions

JP2006510396A5 (fr

JP2006510396A (ja

Inventor

ボーニルソン

ヨナスアンダーソン

カリンカルドウェル

ジェニファーネフ

Original Assignee

アルヴィヴォインコーポレイテッド

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-10-21

Filing date

2003-10-21

Publication date

2012-09-19

2003-10-21 Application filed by アルヴィヴォインコーポレイテッド filed Critical アルヴィヴォインコーポレイテッド

2006-03-30 Publication of JP2006510396A publication Critical patent/JP2006510396A/ja

2006-12-07 Publication of JP2006510396A5 publication Critical patent/JP2006510396A5/ja

2012-09-19 Application granted granted Critical

2012-09-19 Publication of JP5030383B2 publication Critical patent/JP5030383B2/ja

2023-10-21 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

239000011248 coating agent Substances 0.000 title claims description 69
238000000576 coating method Methods 0.000 title claims description 67
150000001875 compounds Chemical class 0.000 title description 5
230000000975 bioactive effect Effects 0.000 title 1
102000016550 Complement Factor H Human genes 0.000 claims description 152
108010053085 Complement Factor H Proteins 0.000 claims description 152
229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 95
230000024203 complement activation Effects 0.000 claims description 84
102000004169 proteins and genes Human genes 0.000 claims description 69
108090000623 proteins and genes Proteins 0.000 claims description 69
230000002209 hydrophobic effect Effects 0.000 claims description 60
229920001400 block copolymer Polymers 0.000 claims description 52
210000004369 blood Anatomy 0.000 claims description 52
239000008280 blood Substances 0.000 claims description 52
239000004971 Cross linker Substances 0.000 claims description 41
238000000034 method Methods 0.000 claims description 41
230000000295 complement effect Effects 0.000 claims description 36
239000004094 surface-active agent Substances 0.000 claims description 35
JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical group O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 claims description 33
229920001577 copolymer Polymers 0.000 claims description 33
229920001451 polypropylene glycol Polymers 0.000 claims description 32
230000001225 therapeutic effect Effects 0.000 claims description 32
108010009575 CD55 Antigens Proteins 0.000 claims description 24
102000050019 Membrane Cofactor Human genes 0.000 claims description 24
101710146216 Membrane cofactor protein Proteins 0.000 claims description 24
125000000524 functional group Chemical group 0.000 claims description 22
125000005647 linker group Chemical group 0.000 claims description 20
HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 claims description 20
229920003229 poly(methyl methacrylate) Polymers 0.000 claims description 20
239000004926 polymethyl methacrylate Substances 0.000 claims description 20
108090000790 Enzymes Proteins 0.000 claims description 17
102000004190 Enzymes Human genes 0.000 claims description 17
229920000642 polymer Polymers 0.000 claims description 17
230000004913 activation Effects 0.000 claims description 15
239000004814 polyurethane Substances 0.000 claims description 14
102000023732 binding proteins Human genes 0.000 claims description 13
108091008324 binding proteins Proteins 0.000 claims description 13
239000003814 drug Substances 0.000 claims description 13
230000005661 hydrophobic surface Effects 0.000 claims description 13
102100037084 C4b-binding protein alpha chain Human genes 0.000 claims description 12
101710159767 C4b-binding protein alpha chain Proteins 0.000 claims description 12
102100035321 Complement factor H-related protein 3 Human genes 0.000 claims description 12
102100035324 Complement factor H-related protein 4 Human genes 0.000 claims description 12
101000878136 Homo sapiens Complement factor H-related protein 3 Proteins 0.000 claims description 12
101000878133 Homo sapiens Complement factor H-related protein 4 Proteins 0.000 claims description 12
102000006834 complement receptors Human genes 0.000 claims description 12
108010047295 complement receptors Proteins 0.000 claims description 12
RDTRHBCZFDCUPW-KWICJJCGSA-N 2-[(4r,7s,10s,13s,19s,22s,25s,28s,31s,34r)-4-[[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]-34-[[(2s,3s)-2-amino-3-methylpentanoyl]amino]-25-(3-amino-3-oxopropyl)-7-[3-(diaminomethylideneamino)propyl]-10,13-bis(1h-imidazol-5-ylmethyl)-19-(1h-indol Chemical compound C([C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CSSC[C@@H](C(N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)NCC(=O)N[C@@H](CC=2NC=NC=2)C(=O)N1)C(C)C)C(C)C)=O)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)C1=CN=CN1 RDTRHBCZFDCUPW-KWICJJCGSA-N 0.000 claims description 11
108010027437 compstatin Proteins 0.000 claims description 11
239000003431 cross linking reagent Substances 0.000 claims description 11
229920002635 polyurethane Polymers 0.000 claims description 11
OTIXUSNHAKOJBX-UHFFFAOYSA-N 1-(aziridin-1-yl)ethanone Chemical compound CC(=O)N1CC1 OTIXUSNHAKOJBX-UHFFFAOYSA-N 0.000 claims description 10
239000005062 Polybutadiene Substances 0.000 claims description 10
101900335902 Vaccinia virus Complement control protein C3 Proteins 0.000 claims description 10
239000003112 inhibitor Substances 0.000 claims description 10
229920002857 polybutadiene Polymers 0.000 claims description 10
150000003462 sulfoxides Chemical class 0.000 claims description 10
125000002228 disulfide group Chemical group 0.000 claims description 8
AWAFMFHOLVZLFG-UHFFFAOYSA-N 1-iodoaziridine-2,3-dione Chemical group IN1C(=O)C1=O AWAFMFHOLVZLFG-UHFFFAOYSA-N 0.000 claims description 7
241000700647 Variola virus Species 0.000 claims description 7
AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical group C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 claims description 7
238000001631 haemodialysis Methods 0.000 claims description 7
230000000322 hemodialysis Effects 0.000 claims description 7
OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine group Chemical group NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 7
125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 claims description 7
125000005413 thiopyridyl group Chemical group 0.000 claims description 7
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 7
239000012634 fragment Substances 0.000 claims description 6
229940124597 therapeutic agent Drugs 0.000 claims description 6
FLCQLSRLQIPNLM-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-acetylsulfanylacetate Chemical compound CC(=O)SCC(=O)ON1C(=O)CCC1=O FLCQLSRLQIPNLM-UHFFFAOYSA-N 0.000 claims description 5
230000002612 cardiopulmonary effect Effects 0.000 claims description 5
230000003213 activating effect Effects 0.000 claims description 4
230000008081 blood perfusion Effects 0.000 claims description 4
210000004204 blood vessel Anatomy 0.000 claims description 4
210000000265 leukocyte Anatomy 0.000 claims description 4
238000002616 plasmapheresis Methods 0.000 claims description 4
238000000108 ultra-filtration Methods 0.000 claims description 4
210000003709 heart valve Anatomy 0.000 claims description 3
235000013599 spices Nutrition 0.000 claims 9
238000001914 filtration Methods 0.000 claims 2
238000006213 oxygenation reaction Methods 0.000 claims 2
230000002792 vascular Effects 0.000 claims 1
239000000463 material Substances 0.000 description 76
239000000758 substrate Substances 0.000 description 76
235000018102 proteins Nutrition 0.000 description 49
230000000694 effects Effects 0.000 description 22
239000004793 Polystyrene Substances 0.000 description 18
239000010935 stainless steel Substances 0.000 description 18
229910001220 stainless steel Inorganic materials 0.000 description 18
206010053567 Coagulopathies Diseases 0.000 description 16
HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 description 16
230000035602 clotting Effects 0.000 description 16
239000000306 component Substances 0.000 description 16
102100022133 Complement C3 Human genes 0.000 description 15
101000901154 Homo sapiens Complement C3 Proteins 0.000 description 15
238000001994 activation Methods 0.000 description 14
239000000872 buffer Substances 0.000 description 14
239000000243 solution Substances 0.000 description 14
229920002223 polystyrene Polymers 0.000 description 13
230000037361 pathway Effects 0.000 description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
238000013459 approach Methods 0.000 description 11
229920001983 poloxamer Polymers 0.000 description 11
-1 antibodies Proteins 0.000 description 10
238000003018 immunoassay Methods 0.000 description 10
210000002966 serum Anatomy 0.000 description 10
230000003993 interaction Effects 0.000 description 9
238000002835 absorbance Methods 0.000 description 8
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 8
HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 8
229910001000 nickel titanium Inorganic materials 0.000 description 8
210000002381 plasma Anatomy 0.000 description 8
108090000765 processed proteins & peptides Proteins 0.000 description 8
238000001179 sorption measurement Methods 0.000 description 8
125000003396 thiol group Chemical group [H]S* 0.000 description 8
238000011282 treatment Methods 0.000 description 8
206010061218 Inflammation Diseases 0.000 description 7
230000008901 benefit Effects 0.000 description 7
230000027455 binding Effects 0.000 description 7
229920002301 cellulose acetate Polymers 0.000 description 7
230000004054 inflammatory process Effects 0.000 description 7
239000004810 polytetrafluoroethylene Substances 0.000 description 7
229920001343 polytetrafluoroethylene Polymers 0.000 description 7
230000002829 reductive effect Effects 0.000 description 7
239000000523 sample Substances 0.000 description 7
108091034117 Oligonucleotide Proteins 0.000 description 6
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 6
238000003312 immunocapture Methods 0.000 description 6
108010090804 Streptavidin Proteins 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
238000001514 detection method Methods 0.000 description 5
238000003618 dip coating Methods 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
229910052751 metal Inorganic materials 0.000 description 5
239000002184 metal Substances 0.000 description 5
230000004071 biological effect Effects 0.000 description 4
235000014633 carbohydrates Nutrition 0.000 description 4
150000001720 carbohydrates Chemical class 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
238000000502 dialysis Methods 0.000 description 4
210000000987 immune system Anatomy 0.000 description 4
238000002513 implantation Methods 0.000 description 4
230000006872 improvement Effects 0.000 description 4
239000000203 mixture Substances 0.000 description 4
230000008569 process Effects 0.000 description 4
102000004196 processed proteins & peptides Human genes 0.000 description 4
239000007790 solid phase Substances 0.000 description 4
229920000428 triblock copolymer Polymers 0.000 description 4
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
102000007330 LDL Lipoproteins Human genes 0.000 description 3
108010007622 LDL Lipoproteins Proteins 0.000 description 3
206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 3
125000003277 amino group Chemical group 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
239000012620 biological material Substances 0.000 description 3
239000007853 buffer solution Substances 0.000 description 3
239000013068 control sample Substances 0.000 description 3
230000008878 coupling Effects 0.000 description 3
238000010168 coupling process Methods 0.000 description 3
238000005859 coupling reaction Methods 0.000 description 3
238000000151 deposition Methods 0.000 description 3
230000008021 deposition Effects 0.000 description 3
231100000673 dose–response relationship Toxicity 0.000 description 3
230000003828 downregulation Effects 0.000 description 3
230000004064 dysfunction Effects 0.000 description 3
230000002526 effect on cardiovascular system Effects 0.000 description 3
238000011534 incubation Methods 0.000 description 3
239000007791 liquid phase Substances 0.000 description 3
239000008363 phosphate buffer Substances 0.000 description 3
238000010188 recombinant method Methods 0.000 description 3
210000000329 smooth muscle myocyte Anatomy 0.000 description 3
230000009885 systemic effect Effects 0.000 description 3
LLXVXPPXELIDGQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)benzoate Chemical compound C=1C=CC(N2C(C=CC2=O)=O)=CC=1C(=O)ON1C(=O)CCC1=O LLXVXPPXELIDGQ-UHFFFAOYSA-N 0.000 description 2
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
102000004506 Blood Proteins Human genes 0.000 description 2
108010017384 Blood Proteins Proteins 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
108010033276 Peptide Fragments Proteins 0.000 description 2
102000007079 Peptide Fragments Human genes 0.000 description 2
229920012266 Poly(ether sulfone) PES Polymers 0.000 description 2
239000004695 Polyether sulfone Substances 0.000 description 2
229920002359 Tetronic® Polymers 0.000 description 2
208000007536 Thrombosis Diseases 0.000 description 2
230000002411 adverse Effects 0.000 description 2
239000012237 artificial material Substances 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000000337 buffer salt Substances 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
239000008199 coating composition Substances 0.000 description 2
230000004154 complement system Effects 0.000 description 2
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
238000004925 denaturation Methods 0.000 description 2
230000036425 denaturation Effects 0.000 description 2
230000006870 function Effects 0.000 description 2
238000002615 hemofiltration Methods 0.000 description 2
229920001477 hydrophilic polymer Polymers 0.000 description 2
230000001976 improved effect Effects 0.000 description 2
210000004969 inflammatory cell Anatomy 0.000 description 2
230000028709 inflammatory response Effects 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
150000002739 metals Chemical class 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical group OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 description 2
230000009871 nonspecific binding Effects 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
244000052769 pathogen Species 0.000 description 2
229920000117 poly(dioxanone) Polymers 0.000 description 2
229920000747 poly(lactic acid) Polymers 0.000 description 2
229920006393 polyether sulfone Polymers 0.000 description 2
229920002689 polyvinyl acetate Polymers 0.000 description 2
239000011118 polyvinyl acetate Substances 0.000 description 2
230000009257 reactivity Effects 0.000 description 2
208000037803 restenosis Diseases 0.000 description 2
125000006850 spacer group Chemical group 0.000 description 2
125000001424 substituent group Chemical group 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
230000001960 triggered effect Effects 0.000 description 2
238000005406 washing Methods 0.000 description 2
125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
108010003529 Alternative Pathway Complement C3 Convertase Proteins 0.000 description 1
206010003210 Arteriosclerosis Diseases 0.000 description 1
108010078015 Complement C3b Proteins 0.000 description 1
102000003712 Complement factor B Human genes 0.000 description 1
108090000056 Complement factor B Proteins 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
102000008946 Fibrinogen Human genes 0.000 description 1
108010049003 Fibrinogen Proteins 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
208000029462 Immunodeficiency disease Diseases 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
102000004856 Lectins Human genes 0.000 description 1
108090001090 Lectins Proteins 0.000 description 1
208000034486 Multi-organ failure Diseases 0.000 description 1
208000010718 Multiple Organ Failure Diseases 0.000 description 1
150000001204 N-oxides Chemical class 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
229920002732 Polyanhydride Polymers 0.000 description 1
229920001710 Polyorthoester Polymers 0.000 description 1
208000004756 Respiratory Insufficiency Diseases 0.000 description 1
206010053879 Sepsis syndrome Diseases 0.000 description 1
229910000831 Steel Inorganic materials 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
239000008351 acetate buffer Substances 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
229940030225 antihemorrhagics Drugs 0.000 description 1
208000011775 arteriosclerosis disease Diseases 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
229920002988 biodegradable polymer Polymers 0.000 description 1
239000004621 biodegradable polymer Substances 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
238000004159 blood analysis Methods 0.000 description 1
239000012503 blood component Substances 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
238000009835 boiling Methods 0.000 description 1
230000021164 cell adhesion Effects 0.000 description 1
230000005779 cell damage Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
208000037887 cell injury Diseases 0.000 description 1
230000012292 cell migration Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
231100000481 chemical toxicant Toxicity 0.000 description 1
239000000788 chromium alloy Substances 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
108010052926 complement C3d,g Proteins 0.000 description 1
230000000536 complexating effect Effects 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000001212 derivatisation Methods 0.000 description 1
150000002019 disulfides Chemical group 0.000 description 1
230000002222 downregulating effect Effects 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
229940012952 fibrinogen Drugs 0.000 description 1
239000012530 fluid Substances 0.000 description 1
102000034356 gene-regulatory proteins Human genes 0.000 description 1
108091006104 gene-regulatory proteins Proteins 0.000 description 1
230000000025 haemostatic effect Effects 0.000 description 1
231100001261 hazardous Toxicity 0.000 description 1
208000031169 hemorrhagic disease Diseases 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
230000003100 immobilizing effect Effects 0.000 description 1
230000005934 immune activation Effects 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
230000007813 immunodeficiency Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
239000002523 lectin Substances 0.000 description 1
230000003908 liver function Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
230000002934 lysing effect Effects 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
238000013508 migration Methods 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
229920006030 multiblock copolymer Polymers 0.000 description 1
208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
230000002107 myocardial effect Effects 0.000 description 1
230000009251 neurologic dysfunction Effects 0.000 description 1
208000015015 neurological dysfunction Diseases 0.000 description 1
238000007344 nucleophilic reaction Methods 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
239000008055 phosphate buffer solution Substances 0.000 description 1
229920001610 polycaprolactone Polymers 0.000 description 1
229920006149 polyester-amide block copolymer Polymers 0.000 description 1
229920005649 polyetherethersulfone Polymers 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
239000012460 protein solution Substances 0.000 description 1
230000004850 protein–protein interaction Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000008085 renal dysfunction Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
201000004193 respiratory failure Diseases 0.000 description 1
238000012552 review Methods 0.000 description 1
239000012723 sample buffer Substances 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
238000002444 silanisation Methods 0.000 description 1
239000010703 silicon Substances 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
239000010959 steel Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000005211 surface analysis Methods 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
230000008718 systemic inflammatory response Effects 0.000 description 1
229910052715 tantalum Inorganic materials 0.000 description 1
GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 1
238000012360 testing method Methods 0.000 description 1
150000003573 thiols Chemical class 0.000 description 1
231100000167 toxic agent Toxicity 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
239000010891 toxic waste Substances 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
YFHICDDUDORKJB-UHFFFAOYSA-N trimethylene carbonate Chemical compound O=C1OCCCO1 YFHICDDUDORKJB-UHFFFAOYSA-N 0.000 description 1

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/0005—Use of materials characterised by their function or physical properties
- A61L33/0011—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
- A61L33/0017—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate using a surface active agent
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/08—Materials for coatings
- A61L29/085—Macromolecular materials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
- A61L29/16—Biologically active materials, e.g. therapeutic substances
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/42—Anti-thrombotic agents, anticoagulants, anti-platelet agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Surgery (AREA)
Vascular Medicine (AREA)
Dermatology (AREA)
Heart & Thoracic Surgery (AREA)
Oral & Maxillofacial Surgery (AREA)
Transplantation (AREA)
Materials Engineering (AREA)
Hematology (AREA)
Materials For Medical Uses (AREA)
Electrotherapy Devices (AREA)
External Artificial Organs (AREA)
Prostheses (AREA)

JP2004546970A 2002-10-21 2003-10-21 生物活性化合物を含む表面コーティング Expired - Fee Related JP5030383B2 (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US42039002P	2002-10-21	2002-10-21
US60/420,390		2002-10-21
PCT/US2003/033348 WO2004037310A2 (fr)	2002-10-21	2003-10-21	Revetement de surface comprenant un compose bioactif

Publications (3)

Publication Number	Publication Date
JP2006510396A JP2006510396A (ja)	2006-03-30
JP2006510396A5 JP2006510396A5 (fr)	2006-12-07
JP5030383B2 true JP5030383B2 (ja)	2012-09-19

Family

ID=32176561

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2004546970A Expired - Fee Related JP5030383B2 (ja)	2002-10-21	2003-10-21	生物活性化合物を含む表面コーティング

Country Status (6)

Country	Link
US (1)	US7459169B2 (fr)
EP (1)	EP1553993B1 (fr)
JP (1)	JP5030383B2 (fr)
AU (1)	AU2003284304B8 (fr)
CA (1)	CA2503490C (fr)
WO (1)	WO2004037310A2 (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20110165244A1 (en) *	2003-10-21	2011-07-07	Allvivo Vascular, Inc.	Bioresponsive polymer formulations for delivery of bioactive agents
US7858108B2 (en) *	2003-10-21	2010-12-28	Richard Nagler	Elutable surface coating
WO2005118020A1 (fr) *	2004-04-21	2005-12-15	Allvivo, Inc.	Revetement surface comprenant un compose bioactif
US20060015057A1 (en) *	2004-07-15	2006-01-19	Ho Chih-Hu	Coating for arterial-venous blood tubing set for hemodialysis system
WO2006078320A2 (fr)	2004-08-04	2006-07-27	Brookwood Pharmaceuticals, Inc.	Procede de production de systemes d'administration, et systemes d'administration
US8168584B2 (en)	2005-10-08	2012-05-01	Potentia Pharmaceuticals, Inc.	Methods of treating age-related macular degeneration by compstatin and analogs thereof
CN103505718B (zh) *	2005-10-08	2018-11-23	阿佩利斯制药公司	用于眼部病症的补体抑制素和其类似物
NZ578341A (en)	2007-01-21	2011-06-30	Hemoteq Ag	Method for producing a coated catheter balloon
US8263104B2 (en) *	2007-06-08	2012-09-11	Northwestern University	Polymer nanofilm coatings
US9192697B2 (en)	2007-07-03	2015-11-24	Hemoteq Ag	Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis
CA2696996C (fr) *	2007-07-16	2016-03-22	The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University	Constructions antimicrobiennes
EP2187957A4 (fr) *	2007-08-31	2011-08-24	Univ Michigan	Dispositifs permettant d'effectuer une cytaphérèse sélective et procédés associés
US8728528B2 (en)	2007-12-20	2014-05-20	Evonik Corporation	Process for preparing microparticles having a low residual solvent volume
DE102008027133A1 (de) *	2008-05-30	2009-12-03	Ls Medcap Gmbh	Vollsynthetisches Albumin-Analogon
US20100040672A1 (en) *	2008-06-09	2010-02-18	Northwestern University	Delivery of therapeutics
US10799593B2 (en)	2008-06-09	2020-10-13	Northwestern University	Nanodiamond particle complexes
US8500687B2 (en)	2008-09-25	2013-08-06	Abbott Cardiovascular Systems Inc.	Stent delivery system having a fibrous matrix covering with improved stent retention
US8226603B2 (en)	2008-09-25	2012-07-24	Abbott Cardiovascular Systems Inc.	Expandable member having a covering formed of a fibrous matrix for intraluminal drug delivery
US8076529B2 (en)	2008-09-26	2011-12-13	Abbott Cardiovascular Systems, Inc.	Expandable member formed of a fibrous matrix for intraluminal drug delivery
US8049061B2 (en)	2008-09-25	2011-11-01	Abbott Cardiovascular Systems, Inc.	Expandable member formed of a fibrous matrix having hydrogel polymer for intraluminal drug delivery
WO2010077646A2 (fr) *	2008-12-30	2010-07-08	Bausch & Lomb Incorporated	Procédé d'application d'un revêtement polymère renouvelable de lentille
US8454689B2 (en) *	2008-12-30	2013-06-04	Bausch & Lomb Incorporated	Brush copolymers
EP2442839B1 (fr)	2009-04-09	2017-10-04	The University of Queensland	Mélanges de copolymères à blocs
EP2944332B1 (fr)	2009-07-10	2016-08-17	Boston Scientific Scimed, Inc.	Utilisation de nanocristaux pour un ballonnet de distribution de médicament
WO2011008393A2 (fr)	2009-07-17	2011-01-20	Boston Scientific Scimed, Inc.	Nucléation de ballons dadministration de médicament pour fournir une taille et une densité des cristaux améliorées
US20110056083A1 (en) *	2009-09-08	2011-03-10	Tsan-Ching Wang	Degradable string for string trimmer
WO2011163394A2 (fr)	2010-06-22	2011-12-29	Apellis Pharmaceuticals, Inc.	Analogues de la compstatine pour le traitement de la douleur neuropathique
US8889211B2 (en)	2010-09-02	2014-11-18	Boston Scientific Scimed, Inc.	Coating process for drug delivery balloons using heat-induced rewrap memory
AU2011315839B2 (en)	2010-10-15	2016-02-18	Seastar Medical Inc.	Cytopheresic cartridge and use thereof
US8669360B2 (en)	2011-08-05	2014-03-11	Boston Scientific Scimed, Inc.	Methods of converting amorphous drug substance into crystalline form
WO2013028208A1 (fr)	2011-08-25	2013-02-28	Boston Scientific Scimed, Inc.	Dispositif médical comprenant un revêtement médicamenteux cristallin
AU2012364759A1 (en)	2011-10-14	2014-06-05	Cytopherx, Inc.	Cartridge and method for increasing myocardial function
ES2780674T3 (es)	2012-11-15	2020-08-26	Apellis Pharmaceuticals Inc	Análogos de compstatina de acción prolongada y composiciones y métodos relacionados
US10308687B2 (en)	2013-03-15	2019-06-04	Apellis Pharmaceuticals, Inc.	Cell-penetrating compstatin analogs and uses thereof
CH708835A1 (de) *	2013-11-14	2015-05-15	Qvanteq Ag	Implantat mit verbesserten Oberflächeneigenschaften.
IL258525B2 (en)	2015-10-07	2023-03-01	Apellis Pharmaceuticals Inc	Dosing regimens
JP2020516607A (ja)	2017-04-07	2020-06-11	アペリス・ファーマシューティカルズ・インコーポレイテッドＡｐｅｌｌｉｓＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	投与レジメンならびに関連組成物および方法
WO2019073992A1 (fr) *	2017-10-11	2019-04-18	国立大学法人京都大学	Filtre à anticorps modifié
DE102019102597A1 (de) *	2019-02-01	2020-08-06	DC Diagnostics Concept UG (haftungsbeschränkt)	Behältnis zur Verwahrung einer Körperflüssigkeit

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2433883C2 (de) *	1973-07-20	1986-03-27	Research Corp., New York, N.Y.	Verwendung von physiologisch aktiven Polypeptiden
SE430062B (sv)	1977-03-04	1983-10-17	Pharmacia Fine Chemicals Ab	Kopplings- eller tioleringsreagens
SE8102194L (sv)	1981-04-06	1982-10-07	Pharmacia Ab	Terapeutiskt aktiv organisk forening och farmaceutisk beredning innehallande denna
JPS6031762A (ja) *	1983-08-03	1985-02-18	テルモ株式会社	人工血管
US4865870A (en)	1988-07-07	1989-09-12	Becton, Dickinson And Company	Method for rendering a substrate surface antithrombogenic
US4975468A (en) *	1989-04-03	1990-12-04	Affinity Biotech, Inc.	Fluorinated microemulsion as oxygen carrier
US5576016A (en) *	1993-05-18	1996-11-19	Pharmos Corporation	Solid fat nanoemulsions as drug delivery vehicles
WO1997035886A1 (fr) *	1996-03-22	1997-10-02	Imutran Limited	Surfaces prevenant ou reduisant l'activation du complement
US5869539A (en) *	1996-04-17	1999-02-09	Board Of Regents, The University Of Texas System	Emulsions of perfluoro compounds as solvents for nitric oxide (NO)
US5877263A (en) *	1996-11-25	1999-03-02	Meadox Medicals, Inc.	Process for preparing polymer coatings grafted with polyethylene oxide chains containing covalently bonded bio-active agents
US6066602A (en) *	1997-08-07	2000-05-23	Becton Dickinson And Company	Waterborne non-silicone lubricant comprising phospholipid and polyether
IT1315220B1 (it)	1999-12-13	2003-02-03	Ipm Ind Plastica Monregalese	Telone di foglia pluristrato di materia plastica per pacciamature e/ocome barriera di contenimento di sostanze di trattamento in
DE60138683D1 (de) *	2000-01-25	2009-06-25	Edwards Lifesciences Corp	Bioaktive beschichtungen zur vermeidung von gewebewachstum auf künstlichen herzklappen
US6926884B2 (en) *	2000-03-02	2005-08-09	Mitsubishi Pharma Corporation	GPIb-lipid bond construct and use thereof
AU2002305924A1 (en) *	2001-02-02	2002-10-08	Allvivo, Inc.	End group activated polymers with oligonucleotide ligands

2003
- 2003-10-21 WO PCT/US2003/033348 patent/WO2004037310A2/fr active Application Filing
- 2003-10-21 EP EP03776485.9A patent/EP1553993B1/fr not_active Expired - Lifetime
- 2003-10-21 CA CA2503490A patent/CA2503490C/fr not_active Expired - Lifetime
- 2003-10-21 JP JP2004546970A patent/JP5030383B2/ja not_active Expired - Fee Related
- 2003-10-21 AU AU2003284304A patent/AU2003284304B8/en not_active Ceased
- 2003-10-21 US US10/689,869 patent/US7459169B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA2503490A1 (fr)	2004-05-06
AU2003284304B8 (en)	2009-08-06
AU2003284304B2 (en)	2009-07-23
US20040142011A1 (en)	2004-07-22
AU2003284304A1 (en)	2004-05-13
US7459169B2 (en)	2008-12-02
EP1553993B1 (fr)	2016-03-30
WO2004037310A3 (fr)	2004-07-01
WO2004037310A2 (fr)	2004-05-06
EP1553993A2 (fr)	2005-07-20
CA2503490C (fr)	2012-04-03
JP2006510396A (ja)	2006-03-30

Publication	Publication Date	Title
JP5030383B2 (ja)	2012-09-19	生物活性化合物を含む表面コーティング
Biran et al.	2017	Heparin coatings for improving blood compatibility of medical devices
Jaffer et al.	2015	Medical device‐induced thrombosis: what causes it and how can we prevent it?
US8048437B2 (en)	2011-11-01	Medical device with surface coating comprising bioactive compound
US6143354A (en)	2000-11-07	One-step method for attachment of biomolecules to substrate surfaces
JP6122052B2 (ja)	2017-04-26	固定化生物学的実体
JPH02147067A (ja)	1990-06-06	ヒルジン被覆生物相容性物質
JP2020108864A (ja)	2020-07-16	固定された生物学的実体
JP5673525B2 (ja)	2015-02-18	抗血液凝固作用を有する親水性高分子化合物
TW201304755A (zh)	2013-02-01	具有抗血栓性之游離血栓捕獲器具
Bricout et al.	2020	Immobilisation of an anti-platelet adhesion and anti-thrombotic drug (EP224283) on polydopamine coated vascular stent promoting anti-thrombogenic properties
US20110165244A1 (en)	2011-07-07	Bioresponsive polymer formulations for delivery of bioactive agents
Hertault et al.	2021	In vivo evaluation of a pro-healing polydopamine coated stent through an in-stent restenosis rat model
Li et al.	2024	Achieving superior anticoagulation of endothelial membrane mimetic coating by heparin grafting at zwitterionic biocompatible interfaces
JP5021313B2 (ja)	2012-09-05	溶出可能な表面コーティング
CA2392080C (fr)	2010-07-27	Surfaces de polymere hemocompatibles
Khanna	2017	Fabrication of human serum albumin film for enhanced Hemocompatibility and mitigation of Neointimal hyperplasia under physiologically relevant flow shear conditions
Belway et al.	2006	Currently available biomaterials for use in cardiopulmonary bypass
Biran et al.	2016	ÔØ Å ÒÙ× Ö ÔØ
Wnek et al.	2008	Heparin-Binding to Improve Biocompatibility/Rolf Larsson
RU2388495C1 (ru)	2010-05-10	Способ получения тромборезистентных полимерных материалов
JP2020065632A (ja)	2020-04-30	医療器具
Bolsinger	2008	Human platelet adhesion to heparinized silica surfaces
Aggarwal	1996	The antithrombotic properties of polymer-coated, drug eluting coronary stents
Scientific et al.	0	AND DEvices: Huv APPLicovs

Legal Events

Date	Code	Title	Description
2006-10-20	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061019
2006-10-20	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20061019
2010-05-27	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100526
2010-08-12	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100811
2010-08-19	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100818
2010-11-26	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101125
2011-01-19	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110118
2011-04-15	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110414
2011-04-22	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110421
2011-07-16	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110715
2011-10-05	A02	Decision of refusal	Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20111004
2012-02-07	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120206
2012-04-10	A911	Transfer to examiner for re-examination before appeal (zenchi)	Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20120409
2012-04-25	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20120406
2012-05-24	TRDD	Decision of grant or rejection written
2012-05-30	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120529
2012-05-31	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01
2012-07-05	A61	First payment of annual fees (during grant procedure)	Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120626
2012-07-06	R150	Certificate of patent or registration of utility model	Ref document number: 5030383 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150
2012-07-09	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20150706 Year of fee payment: 3
2015-04-21	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2016-07-26	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2017-07-11	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2018-03-27	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2019-07-06	LAPS	Cancellation because of no payment of annual fees